RT Journal Article
SR Electronic
T1 Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266241
DO 10.1101/2021.11.11.21266241
A1 Lim, Sing Mei
A1 Cheng, Hoi Lok
A1 Jia, Huan
A1 Kongsuphol, Patthara
A1 D/O Shunmuganathan, Bhuvaneshwari
A1 Chen, Ming Wei
A1 Ng, Say Yong
A1 Gao, Xiaohong
A1 Turaga, Shuvan Prashant
A1 Heussler, Sascha P.
A1 Somani, Joyti
A1 Sengupta, Sharmila
A1 Tay, Dousabel MY
A1 McBee, Megan E.
A1 Young, Barnaby E.
A1 MacAry, Paul A.
A1 Sikes, Hadley D.
A1 Preiser, Peter R.
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.11.21266241.abstract
AB There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic’s changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type, alpha, beta, gamma, and delta variant receptor binding domains. It captures a clinically relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1st dose and post 2nd dose vaccination samples within 10 minutes. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a post-vaccinated population.Competing Interest StatementPK, MM, HDS, JH and PRP are the cofounders of Thrixen Pte Ltd, a start-up company working in further developing some of the technology presented here.Funding StatementThis study is supported by National Health Innovation Singapore (NHIC) grant # NHIC-COVID19-2005004, National Research Foundation via CREATE Share grant #R571-002-021-592 and the Antimicrobial Resistance Interdisciplinary Research Group (AMR-IRG) of Singapore -MIT Alliance in Research and Technology (SMART). All samples acquired from National Centre of Infectious Diseases (NCID) were supported by Singapore Ministry of Healths National Medical Research Council COVID-19 Research Fund: COVID19RF-0008.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Nanyang Technological University gave ethical approval for this work (IRB-2021-04-020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors